Pipeline
About us
  • Founded in 2007
  • Patents 30+
  • R&D personnel 100+
Learn more
News
Good News | CF PharmTech won the
Good News | CF PharmTech won the "Best Employer of Greater Suzhou" in 2022
On November 17, 2022, the 9th "Best Employers in Greater Suzhou" was officially announced by Suzhou Industrial Park Human Resources Development Co., LTD. With excellent human resource management pract
Nov.17.2022
Good news from CF PharmTech | The first domestic blockbuster product for the treatment of allergic rhinitis - Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (ShuFeiMin ®) was approved
Good news from CF PharmTech | The first domestic blockbuster product for the treatment of allergic rhinitis - Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (ShuFeiMin ®) was approved
Today, CF PharmTech, Inc. (hereinafter referred to as: "CF PharmTech") independently developed the heavy product ShuFeiMin® (National drug approval number: H20223778, general
Nov.07.2022
CF PharmTech has completed F round of 360 million yuan equity investment to support rapid development of domestic high-end inhalation products.
CF PharmTech has completed F round of 360 million yuan equity investment to support rapid development of domestic high-end inhalation products.
CF PharmTech, Inc. (CF PharmTech, Inc., referred to as "CF PharmTech"), following the completion of the E round of 630 million financing in January, once again completed the F round of 360 million yuan financing, a total of nearly 1 billion financing with
Jul.03.2020